Global market to grow about 5% in 2009: IMS

Share this article:
IMS Health is forecasting a 4.5% to 5.5% growth in the global pharmaceutical market during 2009, with dollar amounts exceeding $820 billion.

In the US, the pharma market is predicted to grow by 1% to 2%—$287 billion to $297 billion—slightly less than the 2% or 3% rate previously expected, according to IMS Health's 2009 Global Market Forecast, published in October.
IMS projected only 25 to 30 new chemical entities slated for launch in 2009. Four or five of those products, in the areas of acute coronary syndrome, diabetes (Takeda's alogliptin; Novo Nordisk's liraglutide), rheumatoid arthritis (Centocor and Schering-Plough's golimumab) and meningitis (Novartis's Menveo vaccine), could turn out to be blockbusters, according to Diana Conmy, director of market insights for IMS. So-called “pharmerging markets” (China, Brazil, India, South Korea, Mexico, Turkey and Russia) are predicted to show the most growth, with numbers reaching $105 to $115 billion combined, according to the data.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?